Skip to Main Content

Paper Details

A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor-targeting Agent.
Clin Cancer Res
17
2022
Author NameAffiliation
Mark C MarkowskiSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Mario A EisenbergerSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Emmanuel S AntonarakisSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
  • 1 - 3

Datasets

Release 1.2